logo
  • Company
    • About
    • Careers
    • News
    • Honors & Awards
  • Solutions
    • The Galen™ Platform
      • First Read
      • Second Read
    • Ibex Precision Medicine
  • Technology
  • Media
    • Blog
    • Media Library
  • Early Adopter Program
  • Contact Us
logologo
  • Company
    • About
    • Careers
    • News
    • Honors & Awards
  • Solutions
    • The Galen™ Platform
      • First Read
      • Second Read
    • Ibex Precision Medicine
  • Technology
  • Media
    • Blog
    • Media Library
  • Early Adopter Program
  • Contact Us
  • Company
    • About
    • Careers
    • News
    • Honors & Awards
  • Solutions
    • The Galen™ Platform
      • First Read
      • Second Read
    • Ibex Precision Medicine
  • Technology
  • Media
    • Blog
    • Media Library
  • Early Adopter Program
  • Contact Us

AI Cancer Diagnostics Leader Ibex Medical Analytics Expands to the Americas with Appointment of Joel Duckworth

January 7, 2021

Share This Article


Previous

Digital pathology industry veteran, Joel Duckworth will lead Ibex’s growth in the Americas as Chief Revenue Officer

 Tel Aviv, Israel - January 7, 2021 - Ibex Medical Analytics, a pioneer in artificial intelligence (AI)-based cancer diagnostics, today announced the creation of a United States subsidiary and the appointment of Joel Duckworth, an accomplished veteran of the digital pathology market, as its Chief Revenue Officer for the Americas.

Joel comes to Ibex with over 15 years of experience in digital pathology. Most recently, he was Director of Commercial Operations at Philips Digital and Computational Pathology in Asia Pacific where he led cross-regional teams for new market entry and expansion of existing markets. Prior to Asia, he led commercial teams in the US and spearheaded the acquisition of the first US customers. Based out of Seattle, Joel will lead Ibex’s commercial activities for the US, Canada and Latin America focusing on revenue growth and acceleration of its customer pipeline.

“I am very excited to join the Ibex team at a defining point in the company’s growth strategy,” said Joel Duckworth. “Ibex has achieved important milestones recently and is leading with worldwide commercial deployments of AI. I am looking forward to furthering Ibex’s expansion in the Americas, at a time when physicians and providers are becoming ever more aware of the clinical benefits and economic value of AI-augmented diagnostics.”

“We are delighted to have Joel join the Ibex team and will certainly benefit from his unrivalled knowledge and experience of the global pathology industry,” said Stuart Shand, Chief Commercial Officer at Ibex. “The Americas is a focus market for Ibex in 2021. Joel’s leadership augments the recent additions of Dr. David Shulkin and Joe Robinson to our advisory board, and we look forward to supporting our customers transition to an AI-empowered workflow for pathology.”

 


Previous

Share This Article

ABOUT IBEX

We are pioneering AI-powered cancer diagnostics in pathology. We are a multidisciplinary team of entrepreneurs, data scientists, software engineers and medical experts, working together to realize our vision: Transforming cancer diagnosis with AI and improving patient care.

Subscribe to our newsletter

Download White Paper

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer sagittis mi in dapibus efficitur. Donec ut tristique lectus. Nunc dapibus convallis ipsum quis pellentesque. Cras pellentesque laoreet orci vitae porttitor.

DOWNLOAD NOW

Default video

Close
https://ibex-ai.com/wp-content/uploads/2018/04/SampleVideo_1280x720_5mb.mp4
Close

©2020 Ibex Medical Analytics Ltd.All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Contact Us
  • Join Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OKPrivacy policy